Oleksyszyn J, Augustine A J
Dyax Corporation, Cambridge, MA 02138, USA.
Inflamm Res. 1996 Sep;45(9):464-72. doi: 10.1007/BF02252318.
The studies described here examine the involvement of the fibrinolytic cascade and its endogenous inhibitors in the regulation of activity of matrix metalloproteinases and cartilage degradation related to non-inflammatory joint disease, like osteoarthritis. An interleukin-1-induced model of degradation using [35S]-labeled bovine and human articular cartilage explants was utilized. One goal of these studies was to compare the responses of bovine and human articular cartilage. Degradation was not inhibited by alpha 1-PI, PAI-1, alpha 2-macroglobulin, alpha 2-antiplasmin or TIMP-2, when IL-1 alone was added. Addition of human plasminogen to bovine explants, at concentrations found in human synovial fluid, increased degradation by three to four-fold. Under these conditions, the degradation was inhibited effectively by all of the endogenous inhibitors tested, indicating the presence of a cascade where activated chondrocytes are a source of u-PA. Plasminogen activated by u-PA gives plasmin, which is known to further activate pro-stromelysin. Stromelysin is essential for activation of collegenase. Not only TIMP, but also inhibitors at earlier steps of activation like PAI-1, alpha 2-antiplasmin, alpha 1-PI and alpha 2-macroglobulin inhibited degradation, and could provide cartilage protection in vivo. An experiment with human articular cartilage explants showed that very little or no degradation occurred when human articular cartilage explants were stimulated with interleukin-1 alone. Addition of human plasminogen (at physiologically relevant concentrations) resulted in significant degradation, which was inhibited in the same manner as in bovine explants, by inhibitors of the fibrinolytic cascade and TIMP. TIMP is much more efficient in human explants, indicating the limited participation of human plasmin in the degradation of human cartilage. Although speculative, it is possible that in vivo, cartilage degradation could be promoted not only by TIMP/MMP imbalance, but also accelerated by decreased levels of certain serpins in synovial fluid (e.g. PAIs, alpha 2-antiplasmin and alpha 1-PI).
本文所述研究探讨了纤维蛋白溶解级联反应及其内源性抑制剂在基质金属蛋白酶活性调节以及与非炎性关节疾病(如骨关节炎)相关的软骨降解过程中的作用。采用了白细胞介素-1诱导的降解模型,使用[35S]标记的牛和人关节软骨外植体。这些研究的一个目标是比较牛和人关节软骨的反应。单独添加白细胞介素-1时,α1-抗胰蛋白酶、纤溶酶原激活物抑制剂-1、α2-巨球蛋白、α2-抗纤溶酶或金属蛋白酶组织抑制剂-2均不能抑制降解。向牛外植体中添加人血浆纤溶酶原(浓度与人滑液中发现的浓度相同),可使降解增加三至四倍。在这些条件下,所有测试的内源性抑制剂均能有效抑制降解,表明存在一个级联反应,其中活化的软骨细胞是尿激酶型纤溶酶原激活物的来源。尿激酶型纤溶酶原激活物激活的血浆纤溶酶原产生纤溶酶,已知纤溶酶可进一步激活原基质溶解素。基质溶解素对于胶原酶的激活至关重要。不仅金属蛋白酶组织抑制剂,而且激活早期阶段的抑制剂(如纤溶酶原激活物抑制剂-1、α2-抗纤溶酶、α1-抗胰蛋白酶和α2-巨球蛋白)均能抑制降解,并可在体内提供软骨保护。一项关于人关节软骨外植体的实验表明,单独用白细胞介素-1刺激人关节软骨外植体时,几乎不发生或不发生降解。添加人血浆纤溶酶原(在生理相关浓度下)会导致显著降解,其被纤维蛋白溶解级联反应抑制剂和金属蛋白酶组织抑制剂以与牛外植体相同的方式抑制。金属蛋白酶组织抑制剂在人外植体中效率更高,表明人血浆纤溶酶在人软骨降解中的参与有限。尽管具有推测性,但在体内,软骨降解不仅可能由金属蛋白酶组织抑制剂/基质金属蛋白酶失衡促进,还可能因滑液中某些丝氨酸蛋白酶抑制剂(如纤溶酶原激活物抑制剂、α2-抗纤溶酶和α1-抗胰蛋白酶)水平降低而加速。